
    
      Patients in the study will be randomized into two dose groups. Patients in each dose group
      will receive one infusion of 300 mg of HuMax-CD20 followed by 7 weekly infusions of either
      500 or 1000 mg of HuMax-CD20. Disease status will be assessed every 3 months until month 24.
    
  